Benzonal tablets 0,1 g

Quick links

Choose a section

Quick links to important sections

Advertisements

Benzonal tablets 0,1 g

Selected form

Advertisements
Advertisements

Method of action: Anticonvulsant

Treatment option: Hepatitis, Jaundice, Epilepsy

Advertisements

Overview of Benzonal tablets 0,1 g

Benzonal tablets 0,1 g is a medication defined by its active component, Benzobarbital (Benzobarbitone), and is classified as a synthetic prescription drug used to manage neurological hyperexcitability.

Property Description
Active ingredient Benzobarbital (Benzobarbitone)
Form Oral Solid Dosage (Tablet, 0,1 g)
Pharmacological class Anticonvulsant Agent, Barbiturate Derivative
Common use Management of seizure disorders/epilepsy
Origin Synthetic Compound

What Type of Medicine is Benzonal Tablets 0,1 g?

Benzonal tablets 0,1 g is a single-ingredient medication classified pharmacologically as an Anticonvulsant agent and a Barbiturate derivative, clinically recognized for its long-acting profile. The drug is an oral solid dosage form, with the identifier 0,1 g specifying the 100-milligram strength of the active substance within each unit. The active component is Benzobarbital, which is chemically a derivative of Phenobarbital. This classification situates the medicine among agents that act on the central nervous system to modulate neuronal activity, with its use supported by pharmacological studies confirming its efficacy in managing neural stability.


Benzobarbital: Composition and Chemical Origin

The definitional composition centers on the active ingredient, Benzobarbital, which is manufactured through chemical synthesis. Benzobarbital is derived from the established parent compound Phenobarbital and is distinguished chemically as an N-benzoyl derivative. This specific chemical modification, which differentiates Benzobarbital from the parent drug, is often employed to influence the substance's metabolism and duration of action. The final product is a tablet intended for oral intake, composed solely of the active component plus essential pharmaceutical excipients necessary to create the specific oral solid dosage form.


General Purpose of an Anticonvulsant Derivative

The primary purpose of a medication classified as an anticonvulsant is to stabilize the electrical environment of the brain, which is essential for managing seizure disorders and epilepsy. This classification stems from its ability to enhance inhibitory neurotransmission, thereby raising the seizure threshold and reducing the spread of abnormal electrical discharges. Barbiturate derivatives like this one work by slowing down the nervous system, helping to prevent the uncontrolled activity that results in seizures. This stabilizing action provides foundational support for maintaining neurological equilibrium and is typically employed for long-term therapeutic needs in patients with chronic conditions.

Advertisements

What side effects are possible with Benzonal tablets 0,1 g?

Possible side effects and safety information: Benzonal tablets 0,1 g

The safety profile of Benzonal (Benzobarbital), a barbiturate derivative, is structured by government regulatory documents based on reported adverse reactions, their frequency, and the body system affected. The most frequently reported adverse effects are related to Central Nervous System (CNS) depression, which typically includes sedation, drowsiness, lethargy, and residual sedation. These effects are often most pronounced at the initiation of treatment and may lessen with continued exposure.

Adverse effects are officially categorized by System-Organ Class (SOC):

System-Organ Class Examples of Documented Adverse Reactions
Nervous System Sedation, Drowsiness, Ataxia, Vertigo, Confusion
Psychiatric Paradoxical Excitement (in children/older adults), Depression, Suicidal Ideation
Skin & Subcutaneous Various Rashes, Exfoliative Dermatitis, Stevens-Johnson Syndrome (SJS)

Serious adverse reactions documented in regulatory sources include life-threatening severe skin conditions (such as SJS and Toxic Epidermal Necrolysis), profound respiratory depression, and circulatory collapse. Due to its classification as an antiepileptic drug, the medicine carries a safety note regarding the potential for suicidal behavior and ideation.

Safety restrictions apply to certain patient populations and underlying conditions. Benzonal is officially restricted in individuals with severe hepatic or renal impairment or Acute Porphyrias. Furthermore, specific risks are noted for pediatric patients (paradoxical excitement) and older adults (increased risk of confusion). Continued, long-term use is associated with the risks of developing physical dependence and tolerance. Abrupt discontinuation after prolonged use carries the risk of precipitating acute withdrawal reactions, including convulsions.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Benzonal tablets 0,1 g (Benzobarbital) is formally documented in regulatory sources by a progression of severe effects primarily targeting the central nervous and cardiorespiratory systems. The documented clinical presentation typically begins with advancing Central Nervous System (CNS) depression, presenting as profound somnolence, confusion, slurred speech, and decreased reflexes (hyporeflexia), which can progress rapidly to coma. Respiratory function is severely compromised, with respiratory depression being a primary, life-threatening manifestation, accompanied by cardiovascular signs such as profound hypotension and the risk of circulatory collapse.

Severe Benzobarbital overexposure carries the documented risk of acute respiratory failure and death. Due to this documented severity, and because no specific antidote is known for this class of drug, regulatory guidance mandates immediate and definitive action.

Emergency Medical Action Required

Any suspected overexposure to Benzonal requires the patient to seek immediate medical attention. If the individual is struggling to breathe, has collapsed, or cannot be awakened, emergency services must be contacted immediately for urgent care. Management in a clinical setting is limited to symptomatic and supportive treatment, including continuous monitoring of vital signs and ensuring adequate respiratory exchange. Regulatory documents note that patients who are elderly or have pre-existing hepatic or renal impairment are at an increased risk of severe toxicity during an overdose scenario.

Advertisements

Therapeutic Uses of Benzonal tablets 0,1 g

Benzonal is commonly used for its supportive role in managing specific symptom patterns and episodes of heightened discomfort. Its therapeutic applications may include addressing symptoms that interfere with daily functioning, managing episodic or fluctuating manifestations, and assisting with instances of physiological strain or discomfort. Its main utility is applied as short-term, symptomatic assistance to support patients during difficult episodes and functional stability. The substance is classified as an anticonvulsant.

“Benzonal plays a role in managing symptoms related to heightened physiological activity, assisting patients in coping more steadily with symptom fluctuations.”


Easing Episodes of Heightened Symptoms

This domain focuses on symptom clusters that may become intense or disruptive, appearing suddenly or intensifying. Benzonal is applied in addressing symptomatic discomfort that may help patients cope more steadily with these disruptive episodes, contributing to easing the overall symptom load.

Quick Fact: Support for symptoms associated with acute or episodic changes.

Support for Fluctuating Symptom Patterns

Benzonal is commonly used across conditions characterized by episodic or fluctuating manifestations, often relevant in contexts marked by increased discomfort or tension. It is used to offer temporary assistance in symptom stabilization, playing a role in easing the overall symptom burden of recurrent or acute episodes.

Assisting with Temporary Functional Strain

This use covers general clinical scenarios that create noticeable physiological strain or discomfort. Benzonal may assist in clinical settings marked by temporary physiological imbalance, assisting with maintaining functional stability when symptoms become momentarily overwhelming.

Advertisements

Eligibility and Restrictions for Use

Benzonal tablets 0,1 g is contraindicated and must not be used by specific patient populations due to official regulatory findings. The drug is explicitly prohibited for individuals with a known hypersensitivity to barbiturates or a history of acute intermittent porphyria. Use is also excluded for patients with marked hepatic impairment (severe liver disease) and those with severe respiratory disease or a known history of sedative-hypnotic addiction.

Eligibility is conditional for several groups. Use during pregnancy is generally not recommended due to its regulatory classification indicating evidence of human fetal risk. For nursing mothers, caution is required as the drug transfers into breast milk, necessitating monitoring for infant side effects.

Age-related restrictions apply, mandating dosage reductions for older adults due to increased sensitivity. Patients with renal or hepatic impairment that is not severe enough to be an absolute contraindication require conditional use with specific dosage adjustments. Eligibility is otherwise established for adults and older children who do not have any of the listed contraindications.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Benzonal (Benzobarbital), a barbiturate derivative, is defined by two major regulatory domains: pharmacokinetic alteration and pharmacodynamic summation. The medication acts as a strong inducer of hepatic microsomal enzymes, which forms the basis for numerous documented interactions that result in the accelerated metabolism of co-administered substances.

Documented Interaction Outcomes

Interaction Type Interacting Substances/Classes Official Regulatory Outcome
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), Voriconazole, certain HIV/AIDS Antivirals Prohibited due to risk of prolonged effects or loss of co-administered drug efficacy [Source: Regulatory Documents].
Pharmacokinetic (Reduced Exposure) Oral Anticoagulants (e.g., Warfarin), Steroidal Hormones (Contraceptives), Corticosteroids Reduced plasma levels and decreased activity of the co-administered drug via enzyme induction [Source: Regulatory Documents].
Pharmacodynamic (Additive Effect) Alcohol (Ethanol), CNS Depressants (Opioids, Benzodiazepines, other Sedatives) Additive depressant effects including amplified sedation and risk of respiratory depression [Source: Regulatory Documents].
Pharmacokinetic (Increased Exposure) Sodium Valproate / Valproic Acid Documented increase in Benzonal's active component serum levels due to metabolic inhibition [Source: Regulatory Documents].
Absorption Constraint Aluminum-containing Antacids Documented decrease in absorption of Benzonal, leading to reduced serum concentration [Source: Regulatory Documents].

The official labeling notes that interaction risk is a constraint in specific populations; the drug is contraindicated in the presence of marked hepatic damage or premonitory signs of hepatic coma due to heightened accumulation and interaction risk. The documented interaction patterns strictly define co-administration restrictions.

Advertisements

Mechanism of Action

The mechanism of this drug is initiated through chemical decomposition, leading to the generation of highly reactive free-radical species. These intermediates act as a broad oxidative agent, nonspecifically disrupting the structural integrity of bacterial proteins within the skin structures. This targeted chemical action results in a reduction of the microbial population in the treated area, contributing to an alteration in the local physiological environment.

Simultaneously, the drug engages a distinct keratolytic mechanism that affects skin cell processes. It promotes the accelerated shedding of the outer layer of dead skin cells (desquamation) and modifies the accumulation of keratin and cellular debris within the follicular opening. This action physically results in the clearance of blocked structures and influences the flow of materials from the pilosebaceous unit.

The overall effect profile is shaped by a localized peripheral action, concentrated at the site of administration, which promotes the exertion of the oxidative and keratolytic effects directly on the biological targets—bacteria and keratin—without significant systemic distribution, leading to targeted physiological adjustments in the skin.

Advertisements

Dosage and Administration Information

How to Use Benzonal tablets 0,1 g

This section describes the administration principles for Benzonal (0,1 g tablets), focusing on dosage patterns and procedural constraints for this class of anticonvulsant.


Administration Overview

Benzonal is an Oral Solid Dosage administered by swallowing the tablet whole. The specific strength of 0,1 g is equivalent to 100 milligrams of the active component, Benzobarbital. Its use is structured as a long-term continuous treatment for chronic management.


Dosing Protocol and Frequency

The established regimen is highly individualized and is not a fixed dose; it requires clinical titration (gradual adjustment) to identify and maintain the optimal therapeutic concentration. Due to the drug's extended duration of action, the total daily dose is typically administered in divided daily doses to maintain stable drug levels throughout the day.

Any change to the established dosage must be implemented gradually, with an interval of approximately 7 to 10 days between adjustments to ensure the medication reaches a new steady-state concentration.


Procedural Constraints and Special Populations

Official instructions stipulate that abrupt discontinuation is strictly prohibited and the medication must be gradually withdrawn under supervision. Furthermore, the administration requires careful consideration of the patient's physiological status: dose reduction is generally indicated for older adults and for patients with known renal impairment or hepatic disease due to alterations in drug metabolism and clearance.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Benzonal Tablets 0,1 g

Benzonal tablets 0,1 g contains Benzobarbital, which is classified pharmacologically as an Anticonvulsant Agent and a Barbiturate derivative. The research for this medication is characterized by the long history of studies exploring this drug class for neurological conditions. This overview describes the type of research available and the outcomes that were monitored in clinical settings, strictly adhering to scientific neutrality.


Evidence for Use in Managing Seizure Disorders

The research for this medication class was studied for conditions characterized by fluctuating or episodic manifestations (such as seizure disorders and epilepsy). This research included Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that combine data from multiple clinical studies. Researchers designed these trials to explore how symptoms change over time in observed populations.

Studies specifically explored outcomes related to systemic or functional imbalance in the brain associated with recurrent seizures. The main outcomes that were measured included the Seizure Freedom Rate, which tracks the proportion of participants who achieved a period without seizure activity, and measurements of the change in seizure frequency from when the trial began. Additionally, research examined how the medication performed against a placebo or other older comparator seizure medications to contribute to the broader evidence landscape. The evidence contributes to understanding symptom patterns, but findings describe group patterns, not personal outcomes.


Long-Term Research and Treatment Persistence

The research landscape includes trials where the duration of follow-up was observed in controlled clinical trials for periods that were typically short-term (three to six months) or intermediate (up to 12 months). However, some evidence is derived from settings with varying symptom burdens that evaluate daily-life functioning and track patients for multiple years.

These longer studies monitored Treatment Retention Rate, which is the proportion of patients who remain on the study medication over time. Findings describe patterns observed in the studies related to the duration of use. It is important to note that while persistence data exists, follow-up durations were limited in many controlled trials, and long-term effects are not fully established regarding functional outcomes.


Research in Different Patient Groups

The medication was evaluated in a variety of patient groups who have conditions involving periods of heightened symptoms. The populations studied included adults with chronic epilepsy and pediatric groups with various seizure types. Research also explored the use of this medication class in patients with more refractory (treatment-resistant) conditions as part of multi-drug regimens.

The research so far indicates that while studies help show what has been observed in these broad groups, data for certain groups remain insufficient. Therefore, the results apply only to the populations studied.


The Strength of the Evidence and Key Study Limitations

The body of research exploring the anticonvulsant class was evaluated in historical RCTs and observational studies. This research contributes to the broader evidence landscape. Scientific reviewers assess the evidence quality for this pharmacological class.

However, the scientific record notes several research limitation frames. One significant gap is the scarcity of comparative evidence from large, modern RCTs that test this medication class directly against the newest generation of anticonvulsant agents. Additionally, the research focused heavily on endpoints like seizure frequency (a surrogate outcome), with less research examining broader outcomes reflecting daily functioning or activity level over the long term.


What Remains Uncertain in the Research Landscape

Research highlights what is known — and what is still uncertain — about the evidence base for this medication class. Long-term effects are not fully established regarding patient functional status over decades, as follow-up durations were limited in key trials. Furthermore, data for certain groups remain insufficient, and there is limited information for long-term outcomes or patients with specific health conditions. A key research limitation frame is the need for more contemporary trials comparing this treatment class to current therapies.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Benzonal tablets 0,1 g (FAQ)


Q: How quickly is Benzonal tablets 0,1 g expected to start working?

Official information for this class of medication suggests that effects on the central nervous system generally begin within 30 minutes after an oral dose. However, the full therapeutic benefit for managing conditions like seizures depends on reaching stable blood levels, which requires a period of individual dose adjustment to reach stable blood levels.


Q: How long does the effect of Benzonal tablets 0,1 g typically last?

This medication is classified in regulatory documents as a long-acting drug. Its components have a long plasma half-life in adults, meaning it stays in the body for an extended period. This long-lasting profile supports its use for the long-term, continuous management described in regulatory documents.


Q: What should be done if an unexpected side effect occurs while taking Benzonal tablets 0,1 g?

Official patient information advises that for serious or concerning adverse reactions, contacting a healthcare provider immediately is recommended. For effects that are non-serious, regulatory guidance generally suggests informing the healthcare provider at the next scheduled consultation, ensuring all side effects are documented.


Q: Can Benzonal tablets 0,1 g be used during pregnancy or breastfeeding?

Official warnings state that use during pregnancy is associated with potential fetal risk based on regulatory data and is generally not recommended. The medication is known to pass into breast milk, so official caution is advised for nursing mothers. In such cases, official documents note that monitoring of the infant for potential effects like sedation is typically required.


Q: What official warnings are associated with Benzonal tablets 0,1 g?

Regulatory documents include formal warnings, such as those concerning the potential for suicidal thoughts and behavior. There is also a risk of developing severe, potentially fatal skin reactions (like Stevens-Johnson syndrome). Regulatory documents also note the potential for dependence and habit formation associated with the continued use of this drug class.


Q: What are the non-serious side effects that people often worry about with Benzonal tablets 0,1 g?

Regulatory documents most frequently list symptoms related to Central Nervous System (CNS) Depression as the common adverse effects. These generally include drowsiness, somnolence, and lethargy. Official descriptions note that these effects are often most noticeable when treatment begins and are generally considered less serious than the rare, severe reactions.


Q: What is the difference between the 'use' and the 'effect' of this medicine?

Official documents define the use (indication) as the management of chronic conditions like seizure disorders. The effect (pharmacology) is described as the drug's mechanism as a nonselective Central Nervous System (CNS) depressant. This action is what allows the drug to modulate neuronal activity and stabilize the brain's electrical environment to achieve the intended therapeutic outcome.


Q: Is it necessary to finish the entire course of Benzonal tablets 0,1 g?

This medication is intended for long-term continuous treatment as described in the prescribing information. Official instructions emphasize that abrupt cessation is strictly prohibited. Official documents specify that the drug requires gradual withdrawal under medical supervision to help minimize the risk of serious symptoms, such as convulsions, associated with abrupt stopping.


Q: Is the 0,1 g strength standard or are other dosages common?

Regulatory documents indicate that this class of medication is available in multiple tablet strengths. The established total daily dose for this drug class is highly individualized, meaning it is adjusted by a medical professional to the optimal concentration for the patient. The 0,1 g strength is one of several available options.


Q: Is Benzonal tablets 0,1 g the same as other similar medicines?

Benzonal contains Benzobarbital, which is chemically derived from the established anti-seizure medication Phenobarbital. While both belong to the same Barbiturate class, Benzobarbital is a chemically modified version often used to influence its metabolism and duration of action. They are chemically similar but not identical compounds.


Q: Is it normal to feel a bit drowsy when starting Benzonal tablets 0,1 g?

Yes, regulatory descriptions note that drowsiness and sedation are among the most commonly reported adverse effects related to Central Nervous System depression. These effects are often most pronounced at the initiation of treatment but are generally noted to lessen as the body adjusts to the medication.


Q: Is Benzonal tablets 0,1 g commonly prescribed by specialists?

The official use of this medication is for the management of chronic conditions such as epilepsy and seizure disorders. These types of conditions are typically managed or co-managed by medical specialists, often including neurologists.


Q: Are there alternatives to Benzonal tablets 0,1 g described in the official literature?

Regulatory documents mention that the research for this medication class includes studies that examined its performance against other older comparator seizure medications. This comparison contributes to the broader evidence landscape for antiepileptic agents, establishing its place within therapeutic options.


Q: Can Benzonal tablets 0,1 g affect the results of lab tests?

Official information notes that chronic use of this medication has been associated in some cases with changes such as megaloblastic anemia, which may impact blood test results. Because the drug is an enzyme inducer, it can also affect the metabolism of other substances, which may indirectly influence the accuracy of certain lab tests.


Q: Why is Benzonal tablets 0,1 g not available over-the-counter?

This medication is legally classified as a Schedule IV controlled substance under the Federal Controlled Substances Act. This classification is due to its noted potential for abuse and dependence, which is why the drug's distribution is controlled and limited to prescription-only status.


Q: Is it possible to develop a dependency on Benzonal tablets 0,1 g?

Yes, official warnings state that tolerance and both psychological and physical dependence can occur with the continued use of this medication class (barbiturates). As a result, regulatory information for this drug class officially notes that it is considered habit forming.


Q: How is the safety of Benzonal tablets 0,1 g monitored after it is released?

Post-market safety is monitored by government agencies. Official patient information instructs users to report suspected adverse reactions to the manufacturer and/or the national drug regulatory authority (e.g., FDA/MedWatch). These authorities collect and analyze this data to ensure ongoing safety monitoring.


Q: Are there any documented cases of accidental overdose with Benzonal tablets 0,1 g?

Regulatory documents contain an OVERDOSAGE section that describes the potential signs and symptoms associated with acute poisoning from this medication class. The risks described include severe central nervous system and cardiovascular depression, which can lead to coma.


Q: How does Benzonal tablets 0,1 g affect the central nervous system generally?

The drug is classified pharmacologically as a nonselective Central Nervous System (CNS) depressant. This action means it can slow down nervous system activity, producing effects ranging from mild sedation to a deep hypnotic state. In therapeutic doses, it is described as decreasing motor activity and depressing the sensory cortex.


Q: Does Benzonal tablets 0,1 g have a risk of causing allergic reactions?

Yes, official adverse reactions lists include allergic reactions (Acquired Hypersensitivity) as a possibility. These reactions typically involve skin issues like hives or dermatitis, though severe, life-threatening skin conditions are also documented in rare instances.


Q: Is Benzonal tablets 0,1 g considered a scheduled substance?

Yes, this class of medication is designated as a Schedule IV drug under the Federal Controlled Substances Act. This classification is due to its potential for abuse, and it is a key reason for its controlled distribution and prescription requirement.

Advertisements

How should Benzonal tablets 0,1 g be stored and disposed of?

Official Storage Requirements

Benzonal tablets 0,1 g (Benzobarbital) must be stored at Controlled Room Temperature, which is officially maintained between 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed to protect the tablets from excessive moisture and humidity, which can affect product stability. This medication must be stored out of the sight and reach of children to prevent accidental ingestion.

Official Disposal Instructions

Disposal of unused or expired Benzonal tablets must follow regulatory guidance for controlled substances. The preferred method is to use an authorized drug take-back program or collection event. If a take-back option is unavailable, the tablets should be mixed with an unappealing substance, placed in a sealed bag, and discarded in the household trash, as specified by national regulatory bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Benzonal tablets 0,1 g found in:

A-Z Index: